The clinical activity of Fuzeon (in combination with other antiretroviral agents) on plasma HIV RNA levels and CD4 counts have been investigated in two randomised, multicenter, controlled studies (TORO 1 and TORO 2) of Fuzeon of 48 weeks duration.
Fuzeons kliniske aktivitet (i kombination med andre antiretrovirale stoffer) på plasma- hiv- RNA - koncentrationer og CD4- tal er undersøgt i to randomiserede, kontrollerede multicenterstudier (TORO 1 og TORO 2) af 48 ugers varighed.